Heft 1 / Januar 2015

Melatonin

Autoren: Annette Bachmann, Thomas Rabe, Nicole Sänger, Elisabeth Merkle; H.-J. Ahrendt, Chr. Albring, J. Bitzer, Chr. Egarter, K. König, G. Merki, A. O. Mueck (Arbeitskreis „Hormontherapie bei der Frau“)

  1. McCord CP, Allen FP (1917). "Evidences associating pineal gland function with alterations in pigmentation". J Exptl Zool 23 (1): 206–24. doi:10.1002/jez.1400230108.
  2. Coates PM, Blackman MR, Cragg GM, LevineM, Moss J, White JD (2005). Encyclopedia of dietary supplements. New York, N.Y: Marcel Dekker. pp. 457–66. ISBN 0-8247-5504-9.
  3. McCord CP, Allen FP (January 1917). "Evidences associating pineal gland function with alterations in pigmentation". J Exptl Zool 23 (1): 206–24. doi:10.1002/jez.1400230108.
  4. Ler­ner AB, Case JD, Taka­hashi Y (July 1960). "Iso­la­ti­on of me­la­to­nin and 5-me­tho­xy­in­do­le-3-ace­tic acid from bo­vi­ne pi­ne­al glands". J. Biol. Chem. 235: 1992–7. PMID 14415935.
  5. Lynch HJ, Wurt­man RJ, Mos­ko­witz MA, Ar­cher MC, Ho MH; Wurt­man; Mos­ko­witz; Ar­cher; Ho (Ja­nu­a­ry 1975). "Daily rhythm in hu­man urina­ry me­la­to­nin". Sci­ence 187(4172):169–71.
  6. Vanecek J, Sugden D, Weller J., Klein D. C. (1985) Atypical synergisitc alpha 1 und Betaadrenergic regulation of adenosine 3,5 monophosphat and guanosin 3,5, monophosphate in rat pinealocytes. Endokrinology, 116, 2167-2173
  7. Lan­ger SZ. Pre­sy­nap­tic re­gu­la­ti­on of the re­lea­se of ca­techo­la­mi­nes. Pharmacol Rev. 1980 Dec;32(4):337-62.
  8. Wright KP, Ba­dia P, My­ers BL, Plenz­ler SC, Ha­kel M. Cof­fei­ne and light ef­fects on night­ti­me me­la­to­nin and tem­pe­ra­ture levels in sleep-de­pri­ved humans. Brain Res. 1997 Jan 30;747(1):78-84
  9. Reiter R.J. The aging pineal gland and its physiological consequences. BioEssays 1992;14:169-175
  10. Brainard GC, Lewy AJ, Menaker M: Effect of wavelength on the suppression of nocturnal plasma melatonin in  normal volunteers
  11. Maestroni GJ (2001). "The immunotherapeutic potential of melatonin". Expert Opin Investig Drugs 10 (3): 467–76. doi:10.1517/13543784.10.3.467. PMID 11227046.
  12. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM (May 2000). "Evidence for melatonin synthesis in mouse and human bone marrow cells". J. Pineal Res. 28 (4): 193–202. doi:10.1034/j.1600-079X.2000.280401.x. PMID 10831154.
  13. Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, Hara M, Suzuki T, Reiter RJ (March 1995). "Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates". Biochem. Mol. Biol. Int. 35 (3): 627–34. PMID 7773197.
  14. Reiter RJ (1991). "Pineal melatonin: cell biology of its synthesis and of its physiological interactions". Endocr. Rev. 12 (2): 151–80. PMID 1649044.
  15. Levallois P. Dumont M.et al: Effects of electric and magnetic fields from high-power lines on female urinary excretion of 6-sulfatoxymelatonin. In: American journal of epidemiology. Band 154, Nummer 7, Oktober 2001, S. 601–609, ISSN 0002-9262. PMID 11581093.
  16. Pfluger D.H., Minder v: Effects of exposure to 16.7 Hz magnetic fields on urinary 6-hydroxymelatonin sulfate excretion of Swiss railway workers. In: Journal of pineal research. Band 21, Nummer 2, September 1996, S. 91–100, ISSN 0742-3098. PMID 8912234.
  17. Gilad E, Zisapel N: High-affinity binding of melatonin to hemoglobin. In: Biochemical and molecular medicine. Band 56, Nummer 2, Dezember 1995, S. 115–120, ISSN 1077-3150. PMID 8825074.
  18. Lahiri D.K. , Davis D.u. a.: Factors that influence radioimmunoassay of human plasma melatonin: a modified column procedure to eliminate interference. In: Biochemical medicine and metabolic biology. Band 49, Nummer 1, Februar 1993, S. 36–50, ISSN 0885-4505. PMID 8439449.
  19. Pan­di-Pe­rumal SR Me­al­to­nin, Na­ture`s most ver­sa­ti­le bi­o­lo­gi­cal sig­nal? FEBS Jour­nal Vo­lu­me 273, Is­sue 13,2813-2838, July 2006
  20. Acuña-Castro­vie­jo D, Rei­ter RJ, Menén­dez-Peláez A, Pab­los MI, Bur­gos A.J Pi­ne­al Res. 1994 Mar;16(2):100-12.
  21. Sau­man I, Rep­pert SM. Neu­ron. 1996 Nov;17(5):889-900
  22. Rep­pert SM.Melatonin re­cep­tors: mo­le­cu­lar bi­o­lo­gy of a new fa­mily of G pro­te­in-cou­pled re­cep­tors J Biol Rhythms.1997 Dec;12(6): 528-31
  23. Be­cker-And­re M, Wie­sen­berg I, Schae­ren-Wie­mers N, And­re E, MIss­bach M, Sau­rat JH, Carl­berg C. Pi­ne­al gland hor­mo­ne me­la­to­nin binds and ac­ti­va­tes an orphan of t he nucle­ar re­cep­tor su­per­fa­mily. J Biol Chem 1994 Nov 18;269(46):28531-4
  24. Kokkola T, Watson MA, Dowell S, Foord SM, Laitlinen JT. Biochem Biophys Res Commun.1998 Aug 19;249(2):531-6
  25. Cas­so­ne VM; Ro­berts MH, Moo­re RY.Melatonin in­hi­bizs me­ta­bo­lic ac­ti­vi­ty in the rat su­pra­chi­as­ma­tic nuclei. Neu­ro­sci Lett.1987 Oct 16;81(1-2):29-34
  26. Zi­sa­pel N, Ego­zy Y, Lau­don M. In­hi­bi­ti­on of do­pa­mi­ne re­lea­se by me­la­to­nin: Re­gi­o­nal dis­tri­bu­ti­on in the rat brain. Brain Res. 246:161-163 (1982)
  27. Wolf AS (2002) Altern und Hormone. Der Gynäkologe 35: 381–400
  28. Nicolau G, Lakatua D, Sackett-Lunde­en L, Haus E (1985) Circadian and circannual rhythms of hormonal variables in elderly men and women. Chronobiol Int 4: 301–318
  29. Bu­be­nik GA, Blask DE, Brown GM, Ma­est­ro­ni GJ, Pang SF, Rei­ter RJ, Vis­wa­nathan M, Zi­sa­pel N. Pro­spects oft he cli­ni­cal uti­liza­ti­on of me­la­to­nin. Biol Sig­nal Re­cept.1998 Jul-Aug;7(4):195-219
  30. Peschke E, Mühlbauer E (October 2010). "New evidence for a role of melatonin in glucose regulation". Best Pract. Res. Clin. Endocrinol. Metab. 24 (5): 829–41. doi:10.1016/j.beem.2010.09.001. PMID 21112029.
  31. Wald­hau­ser F, Sle­tu B, Trin­chard-Lu­gan I. Sleep la­bo­ra­to­ry in­ves­ti­ga­ti­ons on hyp­no­tic pro­per­ties of me­la­to­nin. Psy­cho­phar­ma­co­lo­gy ( Berl).1990;100(2):222-6
  32. Mills E, Wu P, Seely D, Guyatt G (November 2005). "Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis". J. Pineal Res. 39 (4): 360–6. doi:10.1111/j.1600-079X.2005.00258.x. PMID 16207291.
  33. National Cancer Institute (May 2013). "Topics in complementary and alternative therapies (PDQ)". National Cancer Institute, National Institutes of Health. Retrieved 5 June 2013.
  34. Koppisetti S, Jenigiri B, Terron MP, Tengattini S, Tamura H, Flores LJ, Tan DX, Reiter RJ (October 2008). "Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review". Dig. Dis. Sci. 53 (10): 2592–603. doi:10.1007/s10620-007-0195-5. PMID 18338264.
  35. Tan D, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ (1999). "High physiological levels of melatonin in the bile of mammals". Life Sci. 65 (23): 2523–9. doi:10.1016/S0024-3205(99)00519-6. PMID 10622237.
  36. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (2001). "Sundowning and circadian rhythms in Alzheimer's disease". Am J Psychiatry 158 (5): 704–11. doi:10.1176/appi.ajp.158.5.704. PMID 11329390.
  37. Jan­sen SL, For­bes DA, Dun­can V, Mor­gan DG.Melatonin for cog­ni­ti­ve im­pair­ment. Coch­ra­ne Da­ta­ba­se Syst Rev.2006 Jan 25;(1):CD 003802
  38. Gagnier JJ (August 2001). "The therapeutic potential of melatonin in migraines and other headache types". Altern Med Rev 6 (4): 383–9. PMID 11578254.
  39. Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M (July 2011). "Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial". Int J Geriatr Psychiatry 26 (7): 687–94. doi:10.1002/gps.2582. PMID 20845391.
  40. Tjon Pian Gi CV, Broeren JP, Starreveld JS, Versteegh FG (July 2003). "Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study". Eur. J. Pediatr. 162 (7–8): 554–5. doi:10.1007/s00431-003-1207-x. PMID 12783318.
  41. Dodick DW, Capobianco DJ (2001). "Treatment and management of cluster headache". Curr Pain Headache Rep 5 (1): 83–91. doi:10.1007/s11916-001-0015-0. PMID 11252143.
  42. Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, Whitton C, Tomlinson H, Bennett S, Jardine J, McCaffrey N, Leyland C, Jakeman C, Miles J (2011). "Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial". J Autism Dev Disord 41 (2): 175–84. doi:10.1007/s10803-010-1036-5. PMID 20535539.
  43. Ehrlich SD (2012). University of Maryland Medical Center. "Melatonin." 2011. www.umm.edu/altmed/articles/melatonin-000315.htm
  44. Sharman EH, Sharman KG, Ge YW, Lahiri DK, Bondy SC (April 2004). "Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin". J. Pineal Res. 36 (3): 165–70. doi:10.1046/j.1600-079X.2003.00112.x. PMID 15009506
  45. Acuña-Castroviejo D, Martín M, Macías M, Escames G, León J, Khaldy H, Reiter RJ (2001). "Melatonin, mitochondria, and cellular bioenergetics".J. Pineal Res. 30 (2): 65–74. doi:10.1034/j.1600-079X.2001.300201.x. PMID 11270481. Lay summary – Science Daily.
  46. Maz­zoc­co­li G1, Ca­rug­hi S, Spe­ran­deo M, Pa­zi­en­za V, Giu­li­a­ni F, Tar­qui­ni R. Neu­ro-en­docri­ne cor­re­la­ti­ons of hy­potha­la­mic-pi­tu­ita­ry-thy­ro­id axis in he­althy hu­mans. J Biol Re­gul Ho­me­ost Agents. 2011 Apr-Jun;25(2):249-57.
  47. Bel­las­tel­la A, De Bel­lis A, Bel­las­tel­la G, Es­po­si­to K3. Op­po­si­te In­flu­ence of Light and Blind­ness on Pi­tu­ita­ry–Go­na­dal Func­tion, Front End­ocri­nol (Lau­sanne). 2013; 4: 205.
  48. Lu­bos­hitz­ki R, Dharan M, Gold­man D, Hiss Y, He­rer P, La­vie P. Im­mun­ohis­to­che­mi­cal lo­ca­liza­ti­on of go­nadotro­pin and go­na­dal ste­ro­id re­cep­tors in hu­man pi­ne­al glands. J Clin End­ocri­nol Me­tab (1997) 82:977–81.10.1210/jc.82.3.977
  49. Shang-Mian Y, Ni­les PL, Youn­glai V. Me­la­to­nin re­cep­tors on hu­man gra­nu­lo­se cell mem­bra­nes. J Clin End­ocri­nol Me­tab (1995) 80:1747–9.10.1210/jc.80.5.1747
  50. Cardinali DP, Nagle CA, Rasner JM (1974) Metabolic fate of androgens in the pineal organ: uptake binding to cytoplasm proteins and conversion of testosteron into 5 a reduced metabolites. Endocrinology 95:174
  51. Kau­ppi­la A, Ki­ve­la A, Pa­ka­ri­nen A, Vak­ku­ri O. In­ver­se sea­so­nal re­la­ti­ons­hip bet­we­en me­la­to­nin and ova­ri­an ac­ti­vi­ty in hu­mans in a re­gi­on with a strong sea­so­nal con­trast in lu­mi­no­si­ty. J Clin End­ocri­nol Me­tab (1993) 76:295–301
  52. Saint Louis C (2011). "Dessert, Laid-Back and Legal". New York Times.
  53. Cag­nac­ci A, El­li­ot JA, Yen SS. Amp­li­fi­ca­ti­on of pul­sa­ti­le LH se­cre­ti­on by exo­ge­nous me­la­to­nin in wo­men. J Clin End­ocri­nol Me­tab (1991) 73:210–2.10.1210/jcem-73-1-210
  54. Arendt J, Me­la­to­nin as­says in body flu­ids. J Neu­rak Transm Suppl.1978;(13):265-78
  55. Rei­ter RJ. Me­la­to­nin and hu­man re­pro­duc­tion. Ann Med (1988) 30:103–8.10.3109/07853899808999391
  56. Rei­ter RJ. Pi­ne­al func­tion in the hu­man: im­pli­ca­ti­on for the re­pro­duc­ti­ve phy­si­o­lo­gy. J Obs­tet Gy­ne­col (1986) 6(Suppl 2):77–81.10.3109/01443618609081730
  57. Filadelfi AM, Castrucci AM (1996). "Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates". J. Pineal Res. 20 (4): 175–86. doi:10.1111/j.1600-079X.1996.tb00256.x. PMID 8836950.
  58. Voor­douw BC, Eu­ser R, Ver­donk RE, Alb­er­da BT, de Jong FH, Dro­gen­dijk AC, Fau­ser BC, Co­hen M. Me­la­to­nin and­ m­el­atonin-pro­ges­tin com­bi­na­ti­ons al­ter pi­tu­ita­ry-ova­ri­an func­tion in wo­men and can in­hi­bit ovu­la­ti­on. 1992 Jan;74(1):108-17.
  59. Voor­douw BC, Eu­ser R, Ver­donk RE, Alb­er­da BT, de Jong FH, Dro­gen­dijk AC, Fau­ser BC, Co­hen M. Me­la­to­nin and­ m­el­atonin-pro­ges­tin com­bi­na­ti­ons al­ter pi­tu­ita­ry-ova­ri­an func­tion in wo­men and can in­hi­bit ovu­la­ti­on. 1992 Jan;74(1):108-17.
  60. Voor­douw BCG, Eu­ser R, Ver­donk RER, Alb­er­da BT et al (1992) Me­la­to­nin and me­la­to­nin pro­ges­tin com­bi­na­ti­ons al­ter pi­tu­ita­ry ova­ri­an func­tion in wo­men and can in­hi­bit ovu­la­ti­on. J Clin En4ocri­nol Me­tab 74/1:108 117
  61. Oza­ta M, Bu­lur M, Bin­gol N, Be­hy­an Z, Co­rakci A, Bolu E, et al. Day­ti­me plas­ma me­la­to­nin levels in male hy­po­go­na­dism. J Clin End­ocri­nol Me­tab (1996) 81:18777–81.10.1210/jc.81.5.1877
  62. Lu­bo­sithzky R, Levi M, Shen-Orr Z, Blum­men­feld Z, He­rer P, La­vie P. Long-term me­la­to­nin ad­mi­nist­ra­ti­on does not al­ter pi­tu­ita­ry-go­na­dal hor­mo­ne se­cre­ti­on in nor­mal men. Hum Re­prod (2000) 15:60–5.10.1093/hum­rep/15.1.60
  63. Per­sen­giev S, Ke­ha­jo­va J. In­hi­bi­to­ry ac­ti­ons of me­la­to­nin and struc­tu­ral­ly re­la­ted com­pounds on tes­tos­te­ro­ne pro­duc­tion by mouse ley­dig cells in vi­tro. Cell Bii­o­chem Funct (1991);9:281-286
  64. Medical News Today Circadin (Prolonged-Release Melatonin) For Primary Insomnia Recommended For Approval In The EU (2007)
  65. Rei­ter RJ, Pa­re­des SD, Man­ches­ter LC, et al. Reducing oxi­da­ti­ve/ni­tro­sa­ti­ve stress: a newly-dis­co­vered gen­re for melatonin. Crit Rev Biochem Mol Biol. 2009;44:175–200
  66. Burkhart K, Phelps JR. (2009). Amber lenses to block blue light and improve sleep: a randomized trial. Chronobiol Int. 2009 Dec;26(8):1602-12. doi: 10.3109/07420520903523719.
  67. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC (May 1993). "Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis". J. Pineal Res. 14 (4): 151–68. doi:10.1111/j.1600-079X.1993.tb00498.x. PMID 8102180.
  68. Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC (2005). "Phase-dependent treatment of delayed sleep phase syndrome with melatonin". Sleep 28 (10): 1271–8. PMID 16295212.
  69. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007). "One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?". J. Pineal Res. 42 (1): 28–42. doi:10.1111/j.1600-079X.2006.00407.x. PMID 17198536.
  70. Terman MR, Wirz-Justice A (2009). Chronotherapeutics for Affective Disorders: A Clinician's Manual for Light and Wake Therapy. Basel: S Karger Pub. p. 71. ISBN 3-8055-9120-9.
  71. Hardeland R (2005). "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance". Endocrine 27 (2): 119–30. doi:10.1385/ENDO:27:2:119. PMID 16217125.
  72. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC (May 1993). "Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis". J. Pineal Res. 14 (4): 151–68. PMID 8102180.
  73. Wirz-Justice A (2009). Chronotherapeutics for Affective Disorders: A Clinician's Manual for Light and Wake Therapy. Basel: S Karger Pub. p. 71. ISBN 3-8055-9120-9.
  74. Pohanka M (2011). "Alzheimer´s disease and related neurodegenerative disorders: implication and counteracting of melatonin". Journal of Applied Biomedicine 9: 185–196. doi:10.2478/v10136-011-0003-6.
  75. Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC (2005). "Phase-dependent treatment of delayed sleep phase syndrome with melatonin". Sleep 28 (10): 1271–8. PMID 16295212.
  76. Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC (2005). "Phase-dependent treatment of delayed sleep phase syndrome with melatonin". Sleep 28 (10): 1271–8. PMID 16295212.
  77. Bauer BA, Melatonin side effects: What are the risks?. Mayo Clinic. Retrieved 2011-08-17.
  78. Terman MR, Wirz-Justice A (2009). Chronotherapeutics for Affective Disorders: A Clinician's Manual for Light and Wake Therapy. Basel: S Karger Pub. p. 71. ISBN 3-8055-9120-9.
  79. Ho­ebert M, van der Hei­jden KB, van Geijlswijk IM, Smits MG (2009). "Long-term fol­low-up of me­la­to­nin tre­at­ment in child­ren with ADHD and chronic sleep onset insomnia". J. Pineal Res. 47 (1): 1–7. doi:10.1111/j.1600-079X.2009.00681.x. PMID 19486273.
  80. Cutolo M, Maestroni GJ (2005). "The melatonin-cytokine connection in rheumatoid arthritis". Ann. Rheum. Dis. 64 (8): 1109–11. doi:10.1136/ard.2005.038588. PMC 1755599. PMID 16014678.
  81. Pa­re­des SD et al, Me­la­to­nin and tryp­to­phan ac­ti­vi­ty-rest rhythm, core and pe­ri­phe­ral tem­pe­ra­tu­res, an in­ter­leu­kin levels in the rings­do­ve:chan­ges with age.J Gern­tol A Biol Sci Med Sci.2009 Mar;64(3):340-50.
  82. Lewis Al (1999). Melatonin and the Biological Clock. McGraw-Hill. p. 23. ISBN 0-87983-734-9.
  83. Hughes V. (2011). "Genetic studies probe sleep hormones role in autism". Simons Foundation. sfari.org/news-and-opinion/conference-news/2011/society-for-neuroscience-2011/genetic-studies-probe-sleep-hormones-role-in-autism; 30.4.2014
  84. Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsäter H, Rastam M, Ståhlberg O, Gillberg IC, Delorme R, Chabane N, Mouren-Simeoni MC, Fauchereau F, Durand CM, Chevalier F, Drouot X, Collet C, Launay JM, Leboyer M, Gillberg C, Bourgeron T (2008). "Abnormal melatonin synthesis in autism spectrum disorders". Mol. Psychiatry 13 (1): 90–8. doi:10.1038/sj.mp.4002016. PMC 2199264. PMID 17505466.
  85. Chaturvedi CM (1984). "Effect of Melatonin on the Adrenl and Gonad of the Common Mynah Acridtheres tristis". Australian Journal of Zoology 32 (6): 803–9. doi:10.1071/ZO9840803.
  86. Arias J, Melean E, Valero N, Pons H, Chacín-Bonilla L, Larreal Y, Bonilla E (2003). "[Effect of melatonin on lymphocyte proliferation and production of interleukin-2 (IL-2) and interleukin-1 beta (IL-1 beta) in mice splenocytes]". Invest Clin (in Spanish; Castilian) 44 (1): 41–50. PMID 12703182.
  87. Sri­ni­va­san V, Spence DW, Mo­sco­vitch A, Pan­di-Pe­rumal SR, Trakht I, Brown GM, Car­di­na­li DP. Ma­la­ria:the­ra­peu­tic im­pli­ca­ti­ons of me­la­to­nin. J Pi­ne­al Res 2010 Jan; 48 (1):1-8
  88. Escames, D. Acuña-Castroviejo, L.C. Lopez et al. Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence J Pharm Phar­ma­col, 58 (2006), pp. 1153–1165
  89. Wil­kin­son D1, Bain E2, Wal­lace Me­la­to­nin for wo­men in preg­nancy for neu­ro­pro­tec­tion of the fetus.Cochrane pro­to­col, pre­pa­red and main­tai­ned by The Coch­ra­ne Col­la­bo­ra­ti­on and pub­lis­hed in The Coch­ra­ne Libr­a­ry 2013, Is­sue 5
  90. Topkan E, Tufan H, Yavuz AA, Bacanli D, Onal C, Kosdak S, Yavuz MN (October 2008). "Comparison of the protective effects of melatonin and amifostine on radiation-induced epiphyseal injury". Int. J. Radiat. Biol. 84 (10): 796–802. doi:10.1080/09553000802389678. PMID 18979313.
  91. Rei­ter RJ, Man­ches­ter LC, Tan DX (Sep­tem­ber 2010). "Neu­ro­to­xins: free ra­di­cal me­cha­nisms and me­la­to­nin pro­tec­tion". Curr Neu­ro­phar­ma­col 8 (3): 194–210. doi:10.2174/157015910792246236. PMC 3001213. PMID 21358970.
  92. Bartsch C, Bartch H, Lippert TH (1991) Importance of the pineal gland in reproduction and gynaeco-logical tumours. Geburtshilfe Frauenheilkunde 51/l:1  8
  93. Wang XS, Tip­per S, App­leby PN, Al­len NE, Key TJ, Tra­vis RC. First-mor­ning urina­ry me­la­to­nin and bre­ast can­cer risk in the Guern­sey Study. Am J Epi­de­mi­ol. 2014 Mar 1;179(5):584-93
  94. www.cancerresearchuk.org/can­cer-info/can­cer­stats/ty­pes/bre­ast/risk­fac­tors/bre­ast-can­cer-risk-fac­tors; 21.4.2014
  95. Jia YJ, Lu YS, Wu KJ, et al. Does night work in­crease the risk of bre­ast can­cer? A sys­te­ma­tic re­view and meta-ana­ly­sis of epi­de­mi­o­lo­gi­cal stu­dies. Can­cer Epi­de­mi­ol. 2013;37 (3):197-206.
  96. Kols­tad HA. Nights­hift work and risk of bre­ast can­cer and other can­cers - a cri­ti­cal re­view of the epi­de­mi­o­lo­gic evi­dence. Scand. J. Work En­vi­ron. He­alth 2008;34(1):5-22.
  97. Wang F, Yeung KL, Chan WC, et al. A meta-ana­ly­sis on dose-re­spon­se re­la­ti­ons­hip bet­we­en night shift work and the risk of bre­ast can­cer. Ann On­col 2013;24(11):2724-32.
  98. Kamdar BB, Ter­gas AI, Ma­teen FJ, et al. Night- shift work and risk of bre­ast can­cer: a sys­te­ma­tic re­view and meta- ana­ly­sis. Bre­ast Can­cer Res Tre­at 2013;138(1):291-301.
  99. Meg­dal SP, Kro­en­ke CH, La­den F, et al. Night work and bre­ast can­cer risk: A sys­te­ma­tic re­view and meta-ana­ly­sis. Eur J Can­cer 2005;41(13):2023-32.
  100. Kamdar BB, Ter­gas AI, Ma­teen FJ, et al. Night- shift work and risk of bre­ast can­cer: a sys­te­ma­tic re­view and meta- ana­ly­sis. Bre­ast Can­cer Res Tre­at 2013;138(1):291-301.
  101. Meg­dal SP, Kro­en­ke CH, La­den F, et al. Night work and bre­ast can­cer risk: A sys­te­ma­tic re­view and meta-ana­ly­sis. Eur J Can­cer 2005;41(13):2023-32.
  102. Buja A, Mast­ran­ge­lo G, Pe­ris­si­not­to E, et al. Can­cer in­ci­dence among fe­ma­le flight at­ten­dants: a meta-ana­ly­sis of pub­lis­hed data. J Wo­mens He­alth (Larchmt) 2006;15(1):98-105.
  103. Stevens RG, Blask DE, Brainard GC, et al. Mee­ting re­port: the role of en­vi­ron­men­tal lighting and cir­ca­di­an dis­rup­ti­on in can­cer and other di­sea­ses. En­vi­ron He­alth Per­spect 2007;115(9):1357-62.
  104. Schern­ham­mer ES, Han­kin­son SE. Urin­ary Me­la­to­nin Levels and Post­me­no­pau­sal Bre­ast Can­cer Risk in the Nur­ses' He­alth Study Co­hort. Can­cer Epi­dem Bio­mar Prev 2009;18(1):74-79.
  105. Jia YJ, Lu YS, Wu KJ, et al. Does night work in­crease the risk of bre­ast can­cer? A sys­te­ma­tic re­view and meta-ana­ly­sis of epi­de­mi­o­lo­gi­cal stu­dies. Can­cer Epi­de­mi­ol. 2013;37 (3):197-206.
  106. Kols­tad HA. Nights­hift work and risk of bre­ast can­cer and other can­cers - a cri­ti­cal re­view of the epi­de­mi­o­lo­gic evi­dence. Scand. J. Work En­vi­ron. He­alth 2008;34(1):5-22.
  107. Vi­ja­y­a­lax­mi, Rei­ter RJ, Her­man TS, Meltz ML (De­cem­ber 1996). "Me­la­to­nin and ra­di­o­pro­tec­tion from ge­ne­tic damage: in vivo/in vitro studies with human volunteers". Mutat. Res. 371 (3–4): 221–8. doi:10.1016/S0165-1218(96)90110-X. PMID 9008723.
  108. Vijayalaxmi, Reiter RJ, Herman TS, Meltz ML (February 1998). "Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes". Mutat. Res. 397 (2): 203–8. doi:10.1016/S0027-5107(97)00211-X. PMID 9541644.
  109. Jar­dim-Pe­ras­si BV, Ar­bab AS, Fer­rei­ra LC, Bo­rin TF, Varma NR, Iskander AS, Shankar A, Ali MM, de Campos Zuccari DA. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS One. 2014 Jan 9;9(1):e85311. doi: 10.1371/journal.pone.0085311. eCollection 2014.  www.ncbi.nlm.nih.gov/pmc/articles/PMC3887041/
  110. Weis­haupt JH, Bar­tels C, Pöl­king E, Diet­rich J, Roh­de G, Poeg­ge­ler B, Mer­tens N, Sper­ling S, Bohn M, Hüther G, Schnei­der A, Bach A, Sirén AL, Har­de­land R, Bähr M, Nave KA, Eh­ren­reich H (No­vem­ber 2006). "Re­du­ced oxi­da­ti­ve da­ma­ge in ALS by high-dose en­te­ral me­la­to­nin tre­at­ment". J. Pi­ne­al Res. 41 (4): 313–23. doi:10.1111/j.1600-079X.2006.00377.x. PMID 17014688.
  111. Wolf E, Mi­laz­zo S, Pil­king­ton K, Liu JP, Zwah­len M,            Horn­eber. Me­la­to­nin in can­cer treatment.Cochrane pro­to­col, pre­pa­red and main­tai­ned by The Coch­ra­ne Col­la­bo­ra­ti­on and pub­lis­hed in The Coch­ra­ne Libr­a­ry 2012, Is­sue 10
  112. Kan­dil TS, Mou­sa AA, El-Gen­dy AA, Ab­bas AM (2010). "The po­ten­ti­al therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease". BMC Gastroenterol 10 (7). doi:10.1186/1471-230X-10-7. PMID 20082715.
  113. Lar­do­ne P, Al­va­rez-Sán­chez N, Guer­re­ro J, Car­ril­lo-Vico A. Me­la­to­nin and Glu­co­se Me­ta­bo­lism: Cli­ni­cal Re­le­van­ce. Curr Pharm Des. 2013 Nov 18.
  114. www.mayoclinic.com/he­alth/me­la­to­nin/NS_pa­ti­ent-me­la­to­nin/DSEC­TION=evi­dence; 30.4.2014
  115. Rosenberg SI, Silverstein H, Rowan PT, Olds MJ (March 1998). "Effect of melatonin on tinnitus". Laryngoscope 108 (3): 305–10. doi:10.1097/00005537-199803000-00001. PMID 9504599.
  116. Pirodda A, Raimondi MC, Ferri GG (August 2010). "Exploring the reasons why melatonin can improve tinnitus". Med. Hypotheses 75 (2): 190–1. doi:10.1016/j.mehy.2010.02.018. PMID 20207491.
  117. Hurtuk A, Dome C, Holloman CH, Wolfe K, Welling DB, Dodson EE, Jacob A (2011). "Melatonin: can it stop the ringing?". Ann. Otol. Rhinol. Laryngol. 120 (7): 433–40. PMID 21859051.
  118. Fornaro M, Prestia D, Colicchio S, Perugi G (2010). "A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation". Curr Neuropharmacol 8 (3): 287–304. doi:10.2174/157015910792246227. PMC 3001221. PMID 21358978.
  119. Juszczak M, Michalska M (2006). "[The effect of melatonin on prolactin, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) synthesis and secretion]". Postepy Hig Med Dosw (Online) (in Polish) 60: 431–8. PMID 16921343.
  120. Fi­scher T, Wig­ger-Alb­er­ti W, Els­ner P (1999) Me­la­to­nin in der Der­ma­to­lo­gie. Haut­arzt 50: 5–11
  121. Fi­scher T, Wig­ger-Alb­er­ti W, Els­ner P (1999) Me­la­to­nin in der Der­ma­to­lo­gie. Haut­arzt 50: 5–11
  122. Valtonen M., Niskanen L., Kangas A-P, Koskinen T. (2005): Effect of melatonin-rich night-time milk on sleep and activity in elderly institutionalized subjects. In: Nordic Journal of Psychiatry, 59. Jg., Heft 3, S. 217-221. PMID 16195124
  123. Nacht­milch­kris­tal­le ge­gen Schlaf­lo­sig­keit sind Un­sinn Deut­sches Ärz­te­blatt, 17. Juni 2010. www.aerzteblatt.de/nach­rich­ten/41634/Nacht­milch­kris­tal­le-ge­gen-Schlaf­lo­sig­keit-sind-Un­sinn; 30.4.2014
  124. Tan DX, Hardeland R, Manchester LC, Korkmaz A, Ma S, Rosales-Corral S, Reiter RJ (January 2012). "Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science". J. Exp. Bot. 63 (2): 577–97. doi:10.1093/jxb/err256. PMID 22016420.
  125. Tan DX, Har­de­land R, Man­ches­ter LC, Pa­re­des SD, Kork­maz A, Sainz RM, Mayo JC, Fu­en­tes-Bro­to L, Rei­ter RJ (2010). "The chan­ging bi­o­lo­gi­cal ro­les of me­la­to­nin du­ring evo­lu­ti­on: from an an­ti­o­xi­dant to sig­nals of dar­kness, se­xu­al se­lec­tion and fitness". Biol Rev Camb Philos Soc 85 (3): 607–23. doi:10.1111/j.1469-185X.2009.00118.x. PMID 20039865.
  126. AMVV § 1, Nr. 1
  127. EU Register on nutrition and health claims
  128. Sientific Opinion on the substantiation of health claims related to melatonin and alleviation of subjective feelings of jet lag (ID 1953), and reduction of sleep onset latency, and improvement of sleep quality (ID 1953) pursuant to Article 13(1) of Regulation (EC) No 1924/20061. EFSA Journal 2010; 8(2):1467.
  129. Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2241.
  130. Wurtman RJ US patent 5449683,, "Methods of inducing sleep using melatonin", issued 1995-09-12, assigned to Massachusetts Institute of Technology
  131. Richardson GS (2005). "The human circadian system in normal and disordered sleep". J Clin Psychiatry. 66 Suppl 9: 3–9; quiz 42–3. PMID 16336035.
  132. Zouboulis CC, Makrantonaki E (2006) The role of hormones in intrinsic aging. In: Gilchrest B, Krutmann J (eds) Skin aging. Springer, Berlin Heidelberg New York, pp 55?64
  133. Richardson GS (2005). "The human circadian system in normal and disordered sleep". J Clin Psychiatry. 66 Suppl 9: 3–9; quiz 42–3. PMID 16336035.
  134. Buscemi N. et al. (2006): Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. In: British Medical Journal. Bd. 332, S. 385–393. PMID 16473858
  135. Wade AG, Ford I, Crawford G, McCon­nachie A, Nir T, Lau­don M, Zi­sa­pel N (2010). "Nightly tre­at­ment of pri­ma­ry in­som­nia with pro­lon­ged re­lea­se me­la­to­nin for 6 months: a ran­do­mi­zed pla­ce­bo controlled trial on age and endogenous melatonin as predictors of efficacy and safety". BMC Med 8: 51. doi:10.1186/1741-7015-8-51. PMC 2933606. PMID 20712869.
  136. Arz­nei­mit­tel-Fach­in­for­ma­ti­on Cir­ca­din® (CH, EMA):               http://www.ema.europa.eu/docs/de_DE/docu­ment_libr­a­ry/EPAR_-_Pro­duct_In­for­ma­ti­on/hu­man/000695/WC500026811.pdf; 30.4.14
  1. Wiechmann AF, Chignell CF, Roberts JE (2008). "Influence of dietary melatonin on photoreceptor survival in the rat retina: an ocular toxicity study". Exp. Eye Res. 86 (2): 241–50. doi:10.1016/j.exer.2007.10.015. PMC 2377032. PMID 18078931.
  2. Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C (1999). "Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats". Toxicol. Sci. 50 (2): 271–9. doi:10.1093/toxsci/50.2.271. PMID 10478864.
  3. "FDA Issues Dietary Supplements Final Rule" (Press release). U.S. Food and Drug Administration. 2007-06-22. Retrieved 2009-08-04.
  4. Ka­ber G. Neue Arz­nei­mit­tel: Me­la­to­nin (Cir­ca­din®) Fort­bil­dungs­te­le­gramm Phar­ma­zie 2009;3:275-286
  5. M. Brackmann Me­la­to­nin de­lays pu­ber­ty in the Djun­ga­ri­an hams­ter, Na­tur­wis­sen­schaf­ten, De­cem­ber 1977, Vo­lu­me 64, Is­sue 12, pp 642 -643
  6. Rodriguez RR (January 13, 2010). "Warning Letter". Inspections, Compliance, Enforcement, and Criminal Investigations. U.S. Food and Drug Administration.
  7. "Melatonin". Drugs.com. www.drugs.com/melatonin.html; 30.4.14
  8. www.ipnsm.hscni.net/libr­a­ry/Me­la­to­ninSCG2010.pdf; 24.3.2014
  9. Ka­ber G. Neue Arz­nei­mit­tel: Me­la­to­nin (Cir­ca­din®) Fort­bil­dungs­te­le­gramm Phar­ma­zie 2009;3:275-286
  10. Ri­chard­son G, Zam­mit G, Rod­ri­quez L, et al. Eva­lu­a­ti­on of cir­ca­di­an pha­se-shif­ting ef­fects of ra­mel­te­on in he­althy sub­jects. Tur­key: So­cie­ty for Chro­no­bi­o­lo­gy; 2005. sie­he auch: Ri­chard­son GS, Wang-Wei­gand S, Zhang J, et al. Long-term safe­ty of ra­mel­te­on tre­at­ment in adults with chronic in­som­nia: A 1-year study. Sleep. 2006a;29(Ab­stract Suppl):A233. und Ri­chard­son G, Zee P, Wang-Wei­gand S, Rod­ri­guez L, et al. Cir­ca­di­an pha­se-shif­ting ef­fects of daily ra­mel­te­on in he­althy adults. So­cie­ty for Re­search of Bio­lo­gi­cal Rhythms 10th Bi­en­ni­al Mee­ting Pro­gram and Ab­stracts; May 21–25; 2006b. pp. 131–2. Ab­stract 196.
  11. www.southstaffsandshropshealthcareft.nhs.uk/Ser­vi­ces/Me­di­ci­nes-Ma­na­ge­ment-and-Phar­macy/De­fault/Es­sen­ti­al-Sha­re-Care-Ag­ree­ments/docs/Gui­de­lines/Prescri­bing-Gui­de­lines-Me­la­to­nin-Ver­si­on-2.aspx; 3.4.2014
  12. Sharman EH, Sharman KG, Ge YW, Lahiri DK, Bondy SC (2004). "Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin". J. Pineal Res. 36 (3): 165–70. doi:10.1046/j.1600-079X.2003.00112.x. PMID 15009506
  13. https://www.whatdotheyknow.com/re­quest/118302/re­spon­se/292960/at­tach/3/attachment.pdf; 24.3.2014
  14. www.awmf.org/uploads/tx_szleit­li­ni­en/028-012l_S1_Nicht­or­ga­ni­sche_Schlaf­stö­run­gen_2013-09.pdf; 30.4.2014
  15. Herxheimer A, Petrie KJ (2001): Melatonin for the prevention and treatment of jet lag. In: Cochrane Database Syst. Rev. 1: CD001520
  16. Herx­hei­mer A, Pe­trie KJ. Me­la­to­nin for the pre­ven­ti­on and tre­at­ment of jet lag. Coch­ra­ne Da­ta­ba­se Syst Rev. 2002;(2):CD001520.
  17. Buscemi N. et al. (2006): Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. In: British Medical Journal. Bd. 332, S. 385–393. PMID 16473858
  18. Mills E, Wu P, Seely D, Guyatt G (November 2005). "Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis". J. Pineal Res. 39 (4): 360–6. doi:10.1111/j.1600-079X.2005.00258.x. PMID 16207291.
  19. National Cancer Institute (2013). "Topics in complementary and alternative therapies (PDQ)". National Cancer Institute, National Institutes of Health. www.cancer.gov/cancertopics/pdq/cam/topics-in-cam/healthprofessional/page1/AllPages/Print; 30.4.2014
  20. Koppisetti S, Jenigiri B, Terron MP, Tengattini S, Tamura H, Flores LJ, Tan DX, Reiter RJ (October 2008). "Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review". Dig. Dis. Sci. 53 (10): 2592–603. doi:10.1007/s10620-007-0195-5. PMID 18338264.
  21. Tan D, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ (1999). "High physiological levels of melatonin in the bile of mammals". Life Sci. 65 (23): 2523–9. doi:10.1016/S0024-3205(99)00519-6. PMID 10622237.
  22. Lewy AJ, Nurnberger JI, Wehr TA, Pack D, Becker LE, Powell RL, Newsome DA (1985). "Supersensitivity to light: possible trait marker for manic-depressive illness". Am J Psychiatry 142 (6): 725–7. PMID 4003592.
  23. Whalley LJ, Perini T, Shering A, Bennie J (July 1991). "Melatonin response to bright light in recovered, drug-free, bipolar patients". Psychiatry Res 38 (1): 13–9. doi:10.1016/0165-1781(91)90048-T. PMID 1658841.
  24. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU (October 2001). "Melatonin treatment for age-related insomnia". J. Clin. Endocrinol. Metab. 86 (10): 4727–30. doi:10.1210/jc.86.10.4727. PMID 11600532.
  25. Sack RL, Brandes RW, Kendall AR, Lewy AJ (2000). "Entrainment of free-running circadian rhythms by melatonin in blind people". N. Engl. J. Med. 343 (15): 1070–7. doi:10.1056/NEJM200010123431503. PMID 11027741.
  26. Morera AL, Henry M, de La Varga M (2001). "[Safety in melatonin use]". Actas Esp Psiquiatr (in Spanish; Castilian) 29 (5): 334–7. PMID 11602091.
  27. Terry PD, Villinger F, Bubenik GA, Sitaraman SV (2009). "Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research". Inflamm. Bowel Dis. 15 (1): 134–40. doi:10.1002/ibd.20527. PMID 18626968
  28. Terman MR, Wirz-Justice A (2009). Chronotherapeutics for Affective Disorders: A Clinician's Manual for Light and Wake Therapy. Basel: S Kar­ger Pub. p. 71. ISBN 3-8055-9120-9.
  29. Ho­ebert M, van der Hei­jden KB, van Geijlswijk IM, Smits MG (Au­gust 2009). "Long-term fol­low-up of me­la­to­nin tre­at­ment in child­ren with ADHD and chronic sleep on­set insomnia". J. Pineal Res. 47 (1): 1–7. doi:10.1111/j.1600-079X.2009.00681.x. PMID 19486273.
  30. AMVV § 1, Nr. 1; www.gesetze-im-internet.de/amvv/anlage_1_11.html; 30.4.2014
  31. Arendt J (2000). "Melatonin, circadian rhythms, and sleep". N. Engl. J. Med. 343 (15): 1114–6. doi:10.1056/NEJM200010123431510. PMID 11027748.